CYMABAY THERAPEUTICS INC's ticker is CBAY and the CUSIP is 23257D103. A total of 130 filers reported holding CYMABAY THERAPEUTICS INC in Q1 2021. The put-call ratio across all filers is 2.94 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $894,600 | -78.6% | 60,000 | -87.5% | 0.00% | -77.8% |
Q1 2023 | $4,187,100 | -4.3% | 480,172 | -31.2% | 0.02% | -60.0% |
Q4 2022 | $4,373,325 | -5.7% | 697,500 | -47.4% | 0.04% | +9.8% |
Q3 2022 | $4,638,000 | +4.8% | 1,325,000 | -11.7% | 0.04% | +24.2% |
Q2 2022 | $4,425,000 | +81.3% | 1,499,900 | +91.1% | 0.03% | 0.0% |
Q1 2022 | $2,441,000 | +11.1% | 785,000 | +20.8% | 0.03% | +50.0% |
Q4 2021 | $2,197,000 | +58.4% | 650,000 | +71.0% | 0.02% | +15.8% |
Q3 2021 | $1,387,000 | +6.0% | 380,052 | +26.7% | 0.02% | +18.8% |
Q2 2021 | $1,308,000 | +40.5% | 300,000 | +46.3% | 0.02% | +45.5% |
Q1 2021 | $931,000 | -12.5% | 205,000 | +10.5% | 0.01% | +83.3% |
Q4 2020 | $1,064,000 | -9.0% | 185,518 | -44.6% | 0.01% | -70.0% |
Q2 2020 | $1,169,000 | +267.6% | 335,000 | +55.8% | 0.02% | +150.0% |
Q1 2020 | $318,000 | -50.1% | 215,000 | -33.8% | 0.01% | -42.9% |
Q4 2019 | $637,000 | +537.0% | 325,000 | +2221.4% | 0.01% | +600.0% |
Q2 2019 | $100,000 | – | 14,000 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Foresite Capital Management III, LLC | 1,641,804 | $7,454,000 | 6.54% |
COMMODORE CAPITAL LP | 2,983,513 | $13,545,000 | 5.40% |
Foresite Capital Management IV, LLC | 1,787,094 | $8,113,000 | 0.97% |
Avoro Capital Advisors LLC | 10,300,000 | $46,762,000 | 0.81% |
Boxer Capital, LLC | 4,000,000 | $18,160,000 | 0.62% |
Sio Capital Management, LLC | 562,339 | $2,553,000 | 0.52% |
ACUTA CAPITAL PARTNERS, LLC | 315,341 | $1,432,000 | 0.52% |
CM Management, LLC | 150,000 | $681,000 | 0.51% |
APIS CAPITAL ADVISORS, LLC | 120,000 | $545,000 | 0.50% |
Versant Venture Management, LLC | 543,753 | $2,469,000 | 0.48% |